Macular Degeneration Clinical Trials
Dry Age-Related Macular Degeneration
Study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration.
A study assessing the safety, tolerability, and efficacy of RO7171009 in participants with geographic atrophy secondary to dry age-related macular degeneration (GALLEGO).
Zimura (anti-C5 aptamer) in subjects with geographic atrophy secondary to dry age-related macular degeneration.
Boehringer Ingelheim Pharmaceuticals
Safety, tolerability, and pharmacokinetics of single doses BI 425809.
University of Virginia TOGA
Clinical study to evaluate treatment with ORACEA® (oral doxycycline) for geographic atrophy (TOGA).
A Phase 1b dose escalation evaluation of safety and tolerability and a Phase 2 proof of concept investigation of efficacy and safety of ASP7317 for atrophy secondary to dry age-related macular degeneration.
A genetic screening and registry study to evaluate long-term clinical outcomes and disease progression in subjects with non-central geographic atrophy (GA) who are carriers of high-risk genetic complement variants associated with dry age-related macular degeneration (AMD).